Other News To Note

Santaris Pharma A/S, of Hoersholm, Denmark, obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for treating cardiovascular disorders. Financial terms were not disclosed. Santaris intends to use its Locked Nucleic Acid platform to develop a LNA-based drug targeting miR-33.